Company Number: 13827911

Analysis Date: 2025-07-29 18:46 UTC

1. Risk Rating: LOW
   The company exhibits a strong net asset position relative to liabilities, positive net current assets, and no overdue filings, indicating sound short-term solvency and compliance.

2. Key Concerns:

• Limited scale and operational history: Incorporated in 2022 with only one employee (the director), which may limit operational resilience and growth prospects.
• Reliance on a single director and shareholder controlling 100% of voting rights, which could pose governance risks in the absence of additional management or oversight.
• Minimal fixed assets and limited financial complexity may constrain expansion or signal a very narrow business scope.

3. Positive Indicators:

• Healthy liquidity position with current assets (£35,355) significantly exceeding current liabilities (£4,985), resulting in a strong net current asset position (£30,370) as of the latest accounts.
• Increasing net assets from £18,743 to £29,730 year-on-year, suggesting retained earnings or capital injections supporting financial stability.
• Up-to-date statutory filings with no overdue accounts or confirmation statements, demonstrating regulatory compliance and good governance practices.
• Micro-entity filing status reduces administrative burden while financials remain transparent.

4. Due Diligence Notes:

• Clarify revenue and profitability since no explicit income or profit/loss data is provided; profitability is critical for sustainability assessment.
• Understand the nature of "Other professional, scientific and technical activities" (SIC 74909) to assess market position and business risks.
• Investigate the director’s background beyond occupation (pharmacist) for operational capability and potential conflicts of interest.
• Review cash flow statements or bank statements to confirm liquidity beyond balance sheet snapshots.
• Assess customer concentration and contract terms given the small size and sole director control.